Scientific database and research platform CiteAb announced on Monday the launch of its CiteAb Explore Platform, comprising the Reagent Search Engine and new Image Search Engine.
Built on over a decade of AI-driven data collection combined with expert human curation, CiteAb's database contains 16 million research tools and their use in 40 million publications, covering antibodies, proteins, models, kits and more. As of 2026, instrument data is also included. This data underpins the Explore Platform, which helps researchers identify fit-for-purpose reagents, faster.
The new Image Search tool is designed to enable researchers to rapidly investigate peer-reviewed scientific images. Developed with input from the scientific community, it provides easy access to 850,000 cropped experimental images -- covering 610,000 proteins, 5,000 diseases, and 160,000 cell lines -- linked directly to publications and the reagents used.
Together, the research tools in CiteAb Explore are intended to help researchers cut time spent navigating fragmented data sources, reduce R&D waste, and achieve more reproducible results.
The CiteAb Explore platform is freely accessible to academics, with a paid subscription model for commercial users.
Kelun-Biotech reports fourth indication for sac-TMT approved by NMPA in HR+/HER2- breast cancer
Delonix Bioworks gets IND clearance for DX-104 in China
Innovent Biologics collaborates with Eli Lilly to develop new oncology and immunology treatments
Ascentage Pharma receives China IND clearance for BTK degrader APG‑3288
BioArctic reports higher royalties as Leqembi sales reach JPY20.7bn in Q4 2025
K36 Therapeutics completes first patient cohort dosing for Phase 1 trial of KTX-2001
Cumberland Pharmaceuticals secures FDA Fast Track status for DMD heart‑disease therapy ifetroban
Cizzle Biotechnology secures Canadian patent for lung cancer biomarker test
Biosion reports first patient dosed in Phase 1a/1b trial of BSI-082
AbbVie submits FDA and EMA applications for new upadacitinib indication in NSV
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals